Investigating the role of TET1 in the development of non-alcoholic fatty liver disease
Official title: TET1 in non-alcoholic fatty liver disease development
Funded at Tulane University of Louisiana · NIH-11015818 · Data updated 2026-11-12
This study is looking at how a protein called TET1 affects non-alcoholic fatty liver disease (NAFLD) and aims to find out how it relates to inflammation and liver damage, which could help develop new treatments for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | February 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $384,829 |
| NIH project number | 5R01DK135664-02 |
| Project ID | NIH-11015818 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults over 21 years old who are diagnosed with non-alcoholic fatty liver disease.
✕Less likely to help
Patients with alcoholic liver disease or those under 21 years old may not benefit from this research.
What this research studies
This research aims to explore how the TET1 protein influences the development and progression of non-alcoholic fatty liver disease (NAFLD). It focuses on understanding the relationship between DNA methylation, inflammation, and fibrosis in patients with NAFLD. By studying specific genes associated with this condition, the research seeks to uncover the biochemical mechanisms that contribute to fatty liver disease. Patients may benefit from insights that could lead to new treatment strategies targeting TET1 and its role in liver health.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for preventing or treating non-alcoholic fatty liver disease.
How similar studies have gone: Previous studies have shown promising results in understanding the role of DNA methylation in liver diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Huang, Chiung-Kuei — Tulane University of Louisiana
- Study coordinator: Huang, Chiung-Kuei
Related research
Other NIH-funded projects on the same topics.
-
Role of fat droplets in liver fat and inflammatory signals in NAFLD
A study at Johns Hopkins will explore how fat droplets in the liver influence molecules that drive inflammation and progression of non-alcoholic fatty liver disease (NAFLD) in adults.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
-
How the TET1 gene affects non-alcoholic fatty liver disease
Researchers are looking at whether changes in the TET1 gene and DNA 'tagging' (methylation) play a role in adult non-alcoholic fatty liver disease.
-
Hepatocellular Genetic Clues for Fatty Liver in Hispanic Adults
A large NIH grant helps researchers study why fatty liver develops in Hispanic adults and how genetics interact with lifestyle to affect risk.
-
Toxic fats, vitamin B12 loss, and AHR may drive fatty liver disease
This grant looks at how certain environmental chemicals may trigger liver damage linked to fatty liver disease and how a vitamin found in the blood could be affected.
-
Glutamine and T cells in fatty liver disease
A study explores how liver glutamine levels affect inflammatory CD4+ T cells in fatty liver disease to find potential new ways to reduce liver inflammation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.